NCT02691130 - Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults | Biotech Hunter

Enrollment

224

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2017

Conditions

InfluenzaHealthy

Interventions

BIOLOGICAL

Multimeric 001 (M-001)

Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B

BIOLOGICAL

H5N1 influenza vaccine

Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)

BIOLOGICAL

Saline

0.9% NaCl in double distilled water

Trial Locations (1)

St Istvan St laszlo Hospital, Budapest